Nyxoah’s Genio is a leadless, battery-free, bilateral sleep-apnea implant with massive U.S. upside—but the stock is a high-beta bet on execution, funding, and a patent-court outcome.
Overview
Nyxoah SA is an innovation-led medtech company focused on neuromodulation for obstructive sleep apnea, with a dual listing on Nasdaq and Euronext Brussels. Its core product, the Genio system, is a minimally invasive, leadless and battery-free hypoglossal nerve stimulation therapy designed for patients who do not achieve success with CPAP. The company sells the implant and external system components and benefits from a recurring consumables stream (nightly adhesive patches/activation elements), creating attractive lifetime value per patient once implanted. After FDA PMA in August 2025, the U.S. becomes the dominant opportunity, supported by strong reimbursement and an estimated ~$10B TAM. Genio’s main competitive advantages versus the incumbent Inspire include bilateral stimulation, a simpler single-incision surgical workflow, and elimination of future battery replacement surgeries. The investment case is therefore a classic adoption-curve story: if Nyxoah can scale center-of-excellence penetration, maintain rapid sequential revenue growth, and expand indications (notably CCC), it could become a meaningful category share winner. The bear case centers on legal, financing, and rollout bottlenecks rather than the underlying clinical rationale.